These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 22456437)

  • 1. Osteoporosis-pseudoglioma syndrome: three novel mutations in the LRP5 gene and response to bisphosphonate treatment.
    Tüysüz B; Bursalı A; Alp Z; Suyugül N; Laine CM; Mäkitie O
    Horm Res Paediatr; 2012; 77(2):115-20. PubMed ID: 22456437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoporosis-pseudoglioma syndrome: clinical, genetic, and treatment-response study of 10 new cases in Greece.
    Papadopoulos I; Bountouvi E; Attilakos A; Gole E; Dinopoulos A; Peppa M; Nikolaidou P; Papadopoulou A
    Eur J Pediatr; 2019 Mar; 178(3):323-329. PubMed ID: 30499050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical features, treatment, and follow-up of OPPG and high-bone-mass disorders: LRP5 is a key regulator of bone mass.
    Ren N; Lv S; Li X; Shao C; Wang Z; Mei Y; Yang W; Fu W; Hu Y; Sha L; Hu W; Zhang Z; Wang C
    Osteoporos Int; 2024 Aug; 35(8):1395-1406. PubMed ID: 38625381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and biochemical response to neridronate treatment in a patient with osteoporosis-pseudoglioma syndrome (OPPG).
    Celli M; D'Eufemia P; Persiani P; Turchetti A; Febbo A; D'Alfonso Y; Celli L; Zambrano A
    Osteoporos Int; 2017 Nov; 28(11):3277-3280. PubMed ID: 28866852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three years follow-up of pamidronate therapy in two brothers with osteoporosis-pseudoglioma syndrome (OPPG) carrying an LRP5 mutation.
    Barros ER; Dias da Silva MR; Kunii IS; Lazaretti-Castro M
    J Pediatr Endocrinol Metab; 2008 Aug; 21(8):811-8. PubMed ID: 18825883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Homozygous LRP5 Mutations in Mexican Patients with Osteoporosis-Pseudoglioma Syndrome.
    Astiazarán MC; Cervantes-Sodi M; Rebolledo-Enríquez E; Chacón-Camacho O; Villegas V; Zenteno JC
    Genet Test Mol Biomarkers; 2017 Dec; 21(12):742-746. PubMed ID: 29131652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoporosis-pseudoglioma syndrome in four new patients: identification of two novel LRP5 variants and insights on patients' management using bisphosphonates therapy.
    Abdel-Hamid MS; Elhossini RM; Otaify GA; Abdel-Ghafar SF; Aglan MS
    Osteoporos Int; 2022 Jul; 33(7):1501-1510. PubMed ID: 35106624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fractures on bisphosphonates in osteoporosis pseudoglioma syndrome (OPPG): pQCT shows poor bone density and structure.
    Streeten EA; Ramirez S; Eliades M; Jaimungal S; Chandrasekaran S; Kathleen R; Holmes Morton D; Puffenberger EG; Herskovitz R; Leonard MB
    Bone; 2015 Aug; 77():17-23. PubMed ID: 25892485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoporosis-pseudoglioma syndrome: description of 9 new cases and beneficial response to bisphosphonates.
    Streeten EA; McBride D; Puffenberger E; Hoffman ME; Pollin TI; Donnelly P; Sack P; Morton H
    Bone; 2008 Sep; 43(3):584-90. PubMed ID: 18602879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of growth, puberty, osteoporosis, and the response to long-term bisphosphonate therapy in four patients with osteoporosis-pseudoglioma syndrome.
    Karakilic-Ozturan E; Altunoglu U; Ozturk AP; Kardelen Al AD; Yavas Abali Z; Avci S; Wollnik B; Poyrazoglu S; Bas F; Uyguner ZO; Kayserili H; Darendeliler F
    Am J Med Genet A; 2022 Jul; 188(7):2061-2070. PubMed ID: 35393770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variable Expressivity and Response to Bisphosphonate Therapy in a Family with Osteoporosis Pseudoglioma Syndrome.
    Tallapaka KB; Ranganath P; Dalal A
    Indian Pediatr; 2017 Aug; 54(8):681-683. PubMed ID: 28891484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical femoral fracture in osteoporosis pseudoglioma syndrome associated with two novel compound heterozygous mutations in LRP5.
    Alonso N; Soares DC; V McCloskey E; Summers GD; Ralston SH; Gregson CL
    J Bone Miner Res; 2015 Apr; 30(4):615-20. PubMed ID: 25384351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoporosis-Pseudoglioma in a Mauritanian Child due to a Novel Mutation in LRP5.
    Biha N; Ghaber SM; Hacen MM; Collet C
    Case Rep Genet; 2016; 2016():9814928. PubMed ID: 26904320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A family with osteoporosis pseudoglioma syndrome due to compound heterozygosity of two novel mutations in the LRP5 gene.
    Cheung WM; Jin LY; Smith DK; Cheung PT; Kwan EY; Low L; Kung AW
    Bone; 2006 Sep; 39(3):470-6. PubMed ID: 16679074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Congenital Bilateral Retinal Detachment in Two Siblings with Osteoporosis-Pseudoglioma Syndrome.
    Welinder LG; Robitaille JM; Rupps R; Boerkoel CF; Lyons CJ
    Ophthalmic Genet; 2015; 36(3):276-80. PubMed ID: 25945592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel mutations affecting LRP5 splicing in patients with osteoporosis-pseudoglioma syndrome (OPPG).
    Laine CM; Chung BD; Susic M; Prescott T; Semler O; Fiskerstrand T; D'Eufemia P; Castori M; Pekkinen M; Sochett E; Cole WG; Netzer C; Mäkitie O
    Eur J Hum Genet; 2011 Aug; 19(8):875-81. PubMed ID: 21407258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity.
    Korvala J; Jüppner H; Mäkitie O; Sochett E; Schnabel D; Mora S; Bartels CF; Warman ML; Deraska D; Cole WG; Hartikka H; Ala-Kokko L; Männikkö M
    BMC Med Genet; 2012 Apr; 13():26. PubMed ID: 22487062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Teriparatide increases bone mineral density in a man with osteoporosis pseudoglioma.
    Arantes HP; Barros ER; Kunii I; Bilezikian JP; Lazaretti-Castro M
    J Bone Miner Res; 2011 Dec; 26(12):2823-6. PubMed ID: 21997141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skeletal characteristics associated with homozygous and heterozygous WNT1 mutations.
    Palomo T; Al-Jallad H; Moffatt P; Glorieux FH; Lentle B; Roschger P; Klaushofer K; Rauch F
    Bone; 2014 Oct; 67():63-70. PubMed ID: 25010833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoporosis-pseudoglioma syndrome: Report of two cases and a manifesting carrier.
    Maltese P; Ziccardi L; Iarossi G; Gusson E; D'Agruma L; Marchini G; Buzzonetti L; Nicoletti A; Benedetti S; Bertelli M
    Ophthalmic Genet; 2017; 38(5):473-479. PubMed ID: 28145787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.